NASDAQ:SURF - Surface Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.97 +0.06 (+1.22 %)
(As of 01/22/2019 11:30 AM ET)
Previous Close$4.91
Today's Range$4.87 - $5.16
52-Week Range$3.45 - $18.18
Volume6,242 shs
Average Volume95,742 shs
Market Capitalization$135.92 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SURF
CUSIPN/A
Phone617-714-4096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.63 million

Profitability

Miscellaneous

Employees56
Market Cap$135.92 million
OptionableNot Optionable

Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) posted its earnings results on Tuesday, November, 13th. The company reported ($0.62) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.68) by $0.06. The business earned $1.73 million during the quarter, compared to the consensus estimate of $2 million. View Surface Oncology's Earnings History.

What price target have analysts set for SURF?

4 brokers have issued 1-year target prices for Surface Oncology's shares. Their forecasts range from $17.00 to $26.00. On average, they anticipate Surface Oncology's share price to reach $22.00 in the next year. This suggests a possible upside of 340.0% from the stock's current price. View Analyst Price Targets for Surface Oncology.

What is the consensus analysts' recommendation for Surface Oncology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Surface Oncology.

Has Surface Oncology been receiving favorable news coverage?

News coverage about SURF stock has trended very positive on Tuesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Surface Oncology earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are some of Surface Oncology's key competitors?

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the folowing people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 61)
  • Mr. J. Jeffrey Goater, CEO, Pres, Sec. & Director (Age 44)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)
  • Ms. Jessica Fees, Sr. VP of Fin. & Bus. Operations
  • Dr. Scott C. Chappel, Chief Technology Officer (Age 68)

When did Surface Oncology IPO?

(SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Meeder Asset Management Inc. (0.02%). Company insiders that own Surface Oncology stock include David S Grayzel and Lilly Ventures Fund I Llc. View Institutional Ownership Trends for Surface Oncology.

Which institutional investors are buying Surface Oncology stock?

SURF stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Surface Oncology stock in the last two years include David S Grayzel and Lilly Ventures Fund I Llc. View Insider Buying and Selling for Surface Oncology.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $5.00.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $135.92 million and generates $6.63 million in revenue each year. Surface Oncology employs 56 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is http://www.surfaceoncology.com.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]


MarketBeat Community Rating for Surface Oncology (NASDAQ SURF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  118
MarketBeat's community ratings are surveys of what our community members think about Surface Oncology and other stocks. Vote "Outperform" if you believe SURF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SURF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel